Skip to main content

Advertisement

Log in

The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Selected high-risk women without breast cancer choose to undergo bilateral prophylactic mastectomy (BPM) to reduce their risk of developing the disease. Several studies have reported that BPM significantly reduces, but does not eliminate, breast cancer risk. Few studies have reported rates or trends of BPM use. Patients with unilateral breast cancer are at increased risk for developing cancer in the normal contralateral breast. Some breast cancer patients choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. The risk of contralateral breast cancer is significantly reduced after CPM. Recent studies reported that CPM rates have markedly increased in recent years in the United States. Alternatives to CPM include surveillance with clinical breast examination, mammography, and, potentially, breast MRI. Endocrine therapy with tamoxifen or aromatase inhibitors significantly reduces the risk of contralateral breast cancer and may be more acceptable than CPM for some patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77–84.

    Article  CAS  PubMed  Google Scholar 

  2. Rebbeck TR, Freibel T, Lynch HT, et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004, 22:1055–1062.

    Article  PubMed  Google Scholar 

  3. Lostumbo L, Carbine N, Wallace J, et al.: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004, 4:CD002748.

    PubMed  Google Scholar 

  4. Robbins GF, Berg JW: Bilateral primary breast cancer: a prospective clinicopathological study. Cancer 1964, 17:1501–1527.

    Article  CAS  PubMed  Google Scholar 

  5. Storm HH, Jensen OM: Risk of contralateral breast cancer in Denmark 1943–80. Br J Cancer 1986, 54:483–492.

    CAS  PubMed  Google Scholar 

  6. Prior P, Waterhouse JA: The incidence of bilateral breast cancer: II. A proposed model for the analysis of coincidental tumours. Br J Cancer 1981, 43:615–622.

    CAS  PubMed  Google Scholar 

  7. Adami HO, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer 1985, 55:643–647.

    Article  CAS  PubMed  Google Scholar 

  8. Vaittinen P, Hemminki K: Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 2000, 88:998–1002.

    Article  CAS  PubMed  Google Scholar 

  9. Peralta EA, Ellenhorn JD, Wagman LD, et al.: Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000, 180:439–445.

    Article  CAS  PubMed  Google Scholar 

  10. McDonnell SK, Schaid DJ, Myers JL, et al.: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001, 19:3938–3943.

    CAS  PubMed  Google Scholar 

  11. Herrinton LJ, Barlow WE, Yu O, et al.: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005, 23:4275–4286.

    Article  PubMed  Google Scholar 

  12. van Sprundel TC, Schmidt MK, Rookus MA, et al.: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005, 93:287–292.

    Article  PubMed  Google Scholar 

  13. Guiliano AE, Boolbol S, Degnim A, et al.: Society of Surgical Oncology: position statement on prophylactic mastectomy. Ann Surg Oncol 2007, 14:2425–2427.

    Article  Google Scholar 

  14. McLaughlin CC, Lillquist PP, Edge SB: Surveillance of prophylactic mastectomy. Cancer 2009 Sep 28 (Epub ahead of print).

  15. Goldflam K, Hunt KK, Gershenwald JE, et al.: Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 2004, 101:1977–1986.

    Article  PubMed  Google Scholar 

  16. • Lehman CD, Gatsonis C, Kuhl CK, et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007, 356:1295–1303. This article discusses how breast MRI detects occult synchronous contralateral breast cancer in about 3% of patients.

    Article  CAS  PubMed  Google Scholar 

  17. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003, 56:1038–1045.

    Article  PubMed  Google Scholar 

  18. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676–689.

    Article  CAS  PubMed  Google Scholar 

  19. Metcalfe K, Lynch HT, Ghadirian P, et al.: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328–2335.

    Article  CAS  PubMed  Google Scholar 

  20. • Tuttle TM, Habermann EB, Grund EH, et al.: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007, 25:5203–5209. This article discusses how the use of contralateral prophylactic mastectomy increased by 150% in the United States from 1998 to 2003.

    Article  PubMed  Google Scholar 

  21. Jones NB, Wilson J, Kotur L, et al.: Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol 2009, 16:2691–2696.

    Article  PubMed  Google Scholar 

  22. Sorbero ME, Dick AW, Burke Beckjord E, et al.: Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009, 16:1597–1605.

    Article  PubMed  Google Scholar 

  23. • Metcalfe KA, Lubinski J, Ghadirian P, et al.: Hereditary Breast Cancer Clinical Study Group. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008, 26:1093–1097. This article states that nearly 50% of patients with unilateral breast cancer and a BRCA mutation undergo contralateral prophylactic mastectomy in the United States.

    Article  PubMed  Google Scholar 

  24. Black WC, Nease RF Jr, Tosteson AN Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87:720–31.

    Article  CAS  PubMed  Google Scholar 

  25. Alexander NE, Ross J, Sumner W, et al.: The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med 1996, 11:92–97.

    Article  CAS  PubMed  Google Scholar 

  26. Partridge A, Adloff K, Blood E, et al.: Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008, 100:243–251.

    Article  PubMed  Google Scholar 

  27. Rakovitch E, Franssen E, Kim J, et al.: A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003, 77:285–293.

    Article  PubMed  Google Scholar 

  28. Schrag D, Kuntz KM, Garber JE, et al.: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000, 283:617–624.

    Article  CAS  PubMed  Google Scholar 

  29. Woerdeman LA, Hage JJ, Smeulders MJ, et al.: Skin-sparing mastectomy and immediate breast reconstruction by use of implants: an assessment of risk factors for complications and cancer control in 120 patients. Plast Reconstr Surg 2006, 118:321–330.

    Article  CAS  PubMed  Google Scholar 

  30. Frost MH, Slezak JM, Tran NV, et al.: Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005, 23:7849–7856.

    Article  PubMed  Google Scholar 

  31. Montgomery LL, Tran KN, Heelan MC, et al.: Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 1999, 6:546–552.

    Article  CAS  PubMed  Google Scholar 

  32. Geiger AM, West CN, Nekhlyudov L, et al.: Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 2006, 24:1350–1356.

    Article  PubMed  Google Scholar 

  33. Altschuler A, Nekhlyudov L, Rolnick S, et al.: Positive, negative, and disparate women’s differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J 2008, 14:25–33.

    Article  PubMed  Google Scholar 

  34. Metcalfe K, Esplen MJ, Goel V, et al.: Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004, 13:14–25.

    Article  PubMed  Google Scholar 

  35. Ciatto S, Ambrogetti D, Bonardi R, et al. Prognostic impact of early detection of contralateral primary breast cancer. Tumori 1990, 76:370–373.

    CAS  PubMed  Google Scholar 

  36. Mellink WA, Holland R, Hendriks JH, et al.: The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 1991, 67:1844–1848.

    Article  CAS  PubMed  Google Scholar 

  37. Fisher B, Redmond C: New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991, 83:1278–1280.

    Article  CAS  PubMed  Google Scholar 

  38. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992, 11:117–120.

    PubMed  Google Scholar 

  39. Rutqvist LE, Cedermark B, Glas U, et al.: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991, 83:1299–1306.

    Article  CAS  PubMed  Google Scholar 

  40. Baum M, Budzar AU, Cuzick J, et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131–2139.

    Article  CAS  PubMed  Google Scholar 

  41. Meakin JW, Hayward JL, Panzarella T, et al.: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1996, 37:11–19.

    Article  CAS  PubMed  Google Scholar 

  42. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 351:1451–1467.

  43. Tuttle TM, Jarosek S, Habermann E, et al.: Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009, 27:1362–1367.

    Article  PubMed  Google Scholar 

  44. Fisher ER, Dignam J, Tan-Chiu E, et al.: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999, 86:429–438.

    Article  CAS  PubMed  Google Scholar 

  45. Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993–2000.

    Article  CAS  PubMed  Google Scholar 

  46. Houghton J, George WD, Cuzick J, et al.: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95–102.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Todd M. Tuttle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tuttle, T.M., Abbott, A., Arrington, A. et al. The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer. Curr Oncol Rep 12, 16–21 (2010). https://doi.org/10.1007/s11912-009-0070-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-009-0070-y

Keywords

Navigation